Metastatic prostate cancer survival has not improved over time
OS and disease-specific survival rates in patients with metastatic prostate cancer have not improved in 20 years, according to study results.
The data suggest those factors have not contributed to the prostate cancer mortality rate, which has decreased by 40% in the past 25 years, researchers wrote.
Researchers used the California Cancer Registry to identify 19,336 men aged at least 45 years who presented with metastatic prostate cancer from 1988 to 2009.
Multivariate analyses indicated that rates for OS were significantly improved in men who presented with prostate cancer from 1988 to 1992 (HR=0.78; 95% CI, 0.72-0.85) and 1993 to 1998 (HR=0.79; 95% CI, 0.74-0.86) vs. men who presented with prostate cancer from 2004 to 2009.
Researchers found no significant improvements in disease-specific survival when comparing men who presented with prostate cancer from 1988 to 1997 and 2004 to 2009.
The risk for death was slightly increased in men who presented with prostate cancer from 1998 to 2003 than those who presented from 2004 to 2009 (HR=1.09; 95% CI, 1.02-1.17).
“Survival for men presenting with de novo metastatic prostate cancer has not improved substantially over the last 25 years and likely has not contributed to the observed declines in prostate cancer mortality,” the researchers wrote. “The stage migration associated with PSA screening has resulted in a dramatically reduced incidence of men presenting with metastatic prostate cancer, a diagnosis with persistently poor prognosis.”
Disclosure: The researchers report no relevant financial disclosures.